StockNow
Calendar
Log in
U.S. Markets

Merck (MRK) and SciBrunch Therapeutics Co announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.

StockNow breaking-news AI analysis

Merck closed an exclusive global licensing deal with SciBrunch Therapeutics for preclinical KRAS inhibitor SPR2015, paying $400 million upfront with total potential transaction value reaching $2.13 billion.

News detail

Under the agreement, SciBrunch has granted Merck exclusive rights to develop, manufacture and commercialize SPR2015 worldwide. SciBrunch will receive an upfront payment of USD 400mln and is eligible to receive payments associated with the achievement of certain milestones related to development, commercialization and other activities across multiple indications. The total potential aggregate value of the transaction, including the upfront payment, is USD 2.13bln. The transaction has closed.

1 stocks
MRKMerck & Co., Inc.$148.64Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US official involved in Iran talks says Trump wants a permanent deal with full terms, Al Arabiya reports

Geopolitics

Iranian President Pezeshkian says Iran remains ready for dialogue despite being attacked during previous talks, but pressure and attacks will not force Iran to surrender

U.S. Markets

Nvidia's (NVDA) Board of Directors has authorized a USD 150bln increase to the share repurchase program, raising the remaining total program to USD 235bln

NVDA